Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment

Natural killer (NK) cells are innate immune effectors capable of broad cytotoxicity via germline-encoded receptors and can have conferred cytotoxic potential via the addition of chimeric antigen receptors. Combined with their reduced risk of graft-versus-host disease (GvHD) and cytokine release synd...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2020-12, Vol.12 (12), p.3871
Main Authors: Navin, Ishwar, Lam, Michael T, Parihar, Robin
Format: Article
Language:English
Subjects:
Antigens
Antitumor agents
Cancer
Chimeric antigen receptors
Cytokines
Cytotoxicity
Dendritic cells
Fibroblasts
Genetic engineering
Graft-versus-host reaction
Immunotherapy
Ligands
Lymphocytes
Metabolism
Microenvironments
Natural killer cells
Ovaries
Prostate
Review
Solid tumors
Stem cells
T cell receptors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Natural killer (NK) cells are innate immune effectors capable of broad cytotoxicity via germline-encoded receptors and can have conferred cytotoxic potential via the addition of chimeric antigen receptors. Combined with their reduced risk of graft-versus-host disease (GvHD) and cytokine release syndrome (CRS), NK cells are an attractive therapeutic platform. While significant progress has been made in treating hematological malignancies, challenges remain in using NK cell-based therapy to combat solid tumors due to their immunosuppressive tumor microenvironments (TMEs). The development of novel strategies enabling NK cells to resist the deleterious effects of the TME is critical to their therapeutic success against solid tumors. In this review, we discuss strategies that apply various genetic and non-genetic engineering approaches to enhance receptor-mediated NK cell cytotoxicity, improve NK cell resistance to TME effects, and enhance persistence in the TME. The successful design and application of these strategies will ultimately lead to more efficacious NK cell therapies to treat patients with solid tumors. This review outlines the mechanisms by which TME components suppress the anti-tumor activity of endogenous and adoptively transferred NK cells while also describing various approaches whose implementation in NK cells may lead to a more robust therapeutic platform against solid tumors.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12123871